Free Trial

Akoya Biosciences (AKYA) Stock Forecast & Price Target

Akoya Biosciences logo
$2.11 -0.01 (-0.47%)
(As of 11/22/2024 ET)

Akoya Biosciences - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
5
Buy
3

Based on 8 Wall Street analysts who have issued ratings for Akoya Biosciences in the last 12 months, the stock has a consensus rating of "Hold." Out of the 8 analysts, 5 have given a hold rating, and 3 have given a buy rating for AKYA.

Consensus Price Target

$5.43
157.28% Upside
According to the 8 analysts' twelve-month price targets for Akoya Biosciences, the average price target is $5.43. The highest price target for AKYA is $10.00, while the lowest price target for AKYA is $3.00. The average price target represents a forecasted upside of 157.28% from the current price of $2.11.
Get the Latest News and Ratings for AKYA and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Akoya Biosciences and its competitors.

Sign Up

AKYA Analyst Ratings Over Time

TypeCurrent Forecast
11/24/23 to 11/23/24
1 Month Ago
10/25/23 to 10/24/24
3 Months Ago
8/26/23 to 8/25/24
1 Year Ago
11/24/22 to 11/24/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
3 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
5 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$5.43$6.56$6.56$8.60
Forecasted Upside157.28% Upside128.66% Upside154.36% Upside91.96% Upside
Consensus Rating
Hold
Moderate Buy
Moderate Buy
Buy

AKYA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKYA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akoya Biosciences Stock vs. The Competition

TypeAkoya BiosciencesMedical CompaniesS&P 500
Consensus Rating Score
2.38
2.80
2.50
Consensus RatingHoldModerate BuyModerate Buy
Predicted Upside157.28% Upside27,098.21% Upside7.66% Upside
News Sentiment Rating
Neutral News

See Recent AKYA News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/19/2024Piper Sandler
2 of 5 stars
 Reiterated RatingOverweight ➝ Overweight$4.00 ➝ $3.00+42.86%
11/15/2024Canaccord Genuity Group
1 of 5 stars
 Lower TargetBuy ➝ Buy$6.00 ➝ $3.50+56.25%
11/15/2024Craig Hallum
3 of 5 stars
B. Bonello
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Hold$7.00 ➝ $5.00+59.74%
8/6/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Equal Weight$4.00 ➝ $3.00+50.00%
8/6/2024BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
M. Massaro
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
8/6/2024JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeOverweight ➝ Neutral
3/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$7.00 ➝ $7.50+40.71%
12/14/2023Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral
11/13/2023Stephens
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$14.00 ➝ $9.00+126.70%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 03:15 PM ET.


AKYA Forecast - Frequently Asked Questions

According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Akoya Biosciences is $5.43, with a high forecast of $10.00 and a low forecast of $3.00.

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akoya Biosciences in the last year. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" AKYA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AKYA, but not buy additional shares or sell existing shares.

According to analysts, Akoya Biosciences's stock has a predicted upside of 157.28% based on their 12-month stock forecasts.

Over the previous 90 days, Akoya Biosciences's stock had 1 downgrade by analysts.

Akoya Biosciences has been rated by research analysts at Canaccord Genuity Group, Craig Hallum, and Piper Sandler in the past 90 days.

Analysts like Akoya Biosciences less than other "medical" companies. The consensus rating for Akoya Biosciences is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how AKYA compares to other companies.


This page (NASDAQ:AKYA) was last updated on 11/23/2024 by MarketBeat.com Staff
From Our Partners